Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q5SGD2

UPID:
PPM1L_HUMAN

ALTERNATIVE NAMES:
Protein phosphatase 1-like; Protein phosphatase 2C isoform epsilon

ALTERNATIVE UPACC:
Q5SGD2; Q2M3J2; Q96NM7

BACKGROUND:
The Protein phosphatase 1L, with alternative names Protein phosphatase 1-like and Protein phosphatase 2C isoform epsilon, is integral in regulating the SAPK signaling pathways. It achieves this by associating with MAP3K7/TAK1 and MAP3K5, leading to their dephosphorylation and attenuating their interaction with MAP2K4 or MAP2K6.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Protein phosphatase 1L offers a promising avenue for the development of novel therapeutic approaches by targeting cellular stress response mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.